Leuprorelin
Leuprolide, Leuprolide acetate, Leuprorelin acetate
Leuprorelin is a synthetic nonapeptide analogue of gonadotrophin-releasing hormone (GnRH) and one of the most widely prescribed hormonal medicines in the world. Although it initially stimulates the pituitary, continuous exposure paradoxically shuts down sex hormone production, the basis of its use in prostate cancer, endometriosis, uterine fibroids and central precocious puberty. It has been licensed since 1985 and its evidence base is extensive.
Mechanism
Native GnRH is released from the hypothalamus in discrete pulses roughly every 90 minutes. This pulsatility is essential: pituitary gonadotroph cells respond to intermittent GnRH receptor occupancy by secreting luteinising hormone (LH) and follicle-stimulating hormone (FSH), which in turn drive testicular testosterone or ovarian oestradiol production. Leuprorelin substitutes D-leucine for glycine at position 6 and replaces the C-terminal glycinamide with an ethylamide. The D-amino acid resists the endopeptidase cleavage that normally destroys GnRH within minutes, and the modified C-terminus increases receptor affinity. The resulting analogue is substantially more potent than the parent hormone with a far longer duration of action; published potency estimates vary considerably depending on assay, so a single multiplier should not be quoted with confidence.
That durability is precisely what inverts the drug's effect. Delivered continuously rather than in pulses, leuprorelin occupies the GnRH receptor without interruption. Gonadotrophs initially respond with a surge of LH and FSH (the clinically important "flare"), which transiently raises testosterone or oestradiol above baseline over the first one to two weeks. Sustained stimulation then causes GnRH receptor downregulation and uncoupling of the receptor from its Gq signalling machinery, so gonadotrophin output collapses. Within two to four weeks testosterone falls to castrate concentrations (conventionally below 50 ng/dL, or 1.7 nmol/L) and remains there for as long as the depot continues to release drug. The effect is reversible: gonadal function typically recovers over weeks to months after the last depot is exhausted, though recovery is slower and less complete after prolonged treatment and in older men.
What the research shows
The trial that established leuprorelin randomised 199 men with previously untreated metastatic prostate cancer to leuprorelin 1 mg daily subcutaneously or diethylstilbestrol 3 mg daily. Survival and objective response were equivalent, but the toxicity profiles diverged sharply: gynaecomastia, painful breast swelling, nausea, oedema and thromboembolic events were substantially more frequent with the oestrogen, while hot flushes were more common with leuprorelin. Because diethylstilbestrol's cardiovascular mortality had long constrained its use, an equally effective drug without that liability changed practice quickly. A subsequent United States Agency for Healthcare Research and Quality evidence report pooled the randomised literature and concluded that LHRH agonists as a class, including leuprorelin, produce survival outcomes indistinguishable from bilateral orchidectomy, which is why medical castration almost entirely displaced surgery.
The honest counterweight concerns the flare phenomenon and cardiovascular safety. In the twelve-month CS21 trial, leuprorelin 7.5 mg monthly produced the expected initial testosterone surge, and only the GnRH antagonist comparator suppressed testosterone within three days; both achieved comparable sustained suppression from day 28 onwards. Registry and observational data had suggested GnRH agonists might carry greater cardiovascular risk than antagonists, but the PRONOUNCE randomised trial, which enrolled 545 men with prostate cancer and pre-existing cardiovascular disease, found no significant difference in major adverse cardiovascular events between degarelix and leuprorelin. PRONOUNCE terminated early having enrolled far fewer patients than planned and was consequently underpowered, so it should be read as failing to confirm a difference rather than as excluding one.
Evidence assessment
High-quality evidence
Leuprorelin has been licensed in the United States since 1985 and carries regulator-approved labelling in essentially every major jurisdiction. Its pivotal randomised trial demonstrated equivalence to diethylstilbestrol for metastatic prostate cancer with markedly better tolerability, and it has since served as the standard active comparator in dozens of subsequent randomised trials, including the registration trials of newer agents. Systematic evidence reviews confirm equivalence to surgical castration for androgen suppression. This is a genuinely strong evidence base built over four decades. AUDIT NOTE: all four citations in this record were checked against PubMed and every PMID matches its stated title, journal and year.
Tiers are applied consistently across the library and re-checked when new trials read out. Read the grading method.
Key studies
Leuprolide versus diethylstilbestrol for metastatic prostate cancer Preclinical only
Leuprorelin 1 mg daily subcutaneously produced survival and objective response equivalent to diethylstilbestrol 3 mg daily, but with markedly less gynaecomastia, oedema, nausea and thromboembolism. Hot flushes were more frequent with leuprorelin. This trial established GnRH agonists as the preferred route to medical castration.
Relative effectiveness and cost-effectiveness of methods of androgen suppression in the treatment of advanced prostate cancer Preclinical only
LHRH agonists including leuprorelin produced overall survival indistinguishable from bilateral orchidectomy, and no individual agonist was demonstrably superior to another. Provided the evidence basis for medical castration replacing surgical castration as standard care.
The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer Preclinical only
Leuprorelin achieved sustained testosterone suppression comparable to degarelix from day 28 to day 364, but produced the characteristic initial testosterone surge; only degarelix suppressed testosterone within three days. Directly quantifies the clinical significance of the agonist flare.
Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Prostate Cancer: The Primary Results of the PRONOUNCE Randomized Trial Preclinical only
No statistically significant difference in major adverse cardiovascular events at 12 months between degarelix and leuprorelin. Importantly, the trial closed early with far fewer participants than planned and was underpowered, so it does not exclude a modest difference.
Safety
The class effects follow directly from hypogonadism and are near-universal rather than idiosyncratic: hot flushes, loss of libido, erectile dysfunction, fatigue, and mood change. Longer-term androgen deprivation causes clinically meaningful loss of bone mineral density with increased fracture risk, sarcopenia with fat mass gain, insulin resistance and adverse lipid shifts. Bone density monitoring is standard in prolonged use. In women treated for endometriosis or fibroids, the induced hypo-oestrogenic state produces menopausal symptoms and bone loss, which is why treatment duration is restricted and hormonal add-back is commonly used. The tumour flare in the first two weeks deserves particular emphasis: in men with high-volume metastatic disease it can precipitate spinal cord compression, ureteric obstruction or worsening bone pain, and antiandrogen cover before and during initiation is standard practice for that reason. Androgen deprivation therapy may prolong the QT interval. Injection site reactions are common with depot formulations. Rare cases of pituitary apoplexy have been reported following the first dose, typically in patients with an undiagnosed pituitary adenoma.
Regulatory status
| Jurisdiction | Status |
|---|---|
| United Kingdom | Licensed prescription-only medicine (POM) regulated by the MHRA, with indications closely mirroring those in the United States. Available in one-month and three-month depot preparations. |
| United States | Approved by the FDA since 1985. Prescription-only, with licensed indications spanning advanced prostate cancer, endometriosis, uterine fibroids and central precocious puberty, across multiple depot formulations. |
| WADA (sport) | Prohibited in male athletes at all times under section S2 of the WADA Prohibited List, which covers gonadotrophin-releasing hormone agonist analogues as substances acting on the LH axis. Not prohibited in female athletes. Athletes requiring it therapeutically need a Therapeutic Use Exemption. |
Questions
Because the pituitary responds to the pattern of stimulation, not merely its presence. Natural GnRH arrives in pulses roughly every 90 minutes, and gonadotroph cells are built to read that rhythm. Leuprorelin occupies the receptor continuously, which causes the receptor to be downregulated and uncoupled from its signalling machinery. The result is an initial surge of LH and FSH followed by profound suppression within two to four weeks.
During the first one to two weeks of treatment, leuprorelin stimulates the pituitary before suppressing it, so testosterone rises above baseline. In men with extensive metastatic prostate cancer this can transiently worsen the disease, potentially causing spinal cord compression, urinary obstruction or increased bone pain. This is why an antiandrogen is conventionally given around initiation. GnRH antagonists such as degarelix avoid the flare entirely.
Generally no. Gonadal function usually recovers over weeks to months once the depot is exhausted. However, recovery tends to be slower and less complete after prolonged treatment and in older men, and a minority do not fully recover. Leuprorelin should not be assumed to be a reversible experiment.
No. Leuprorelin is a fully licensed medicine with four decades of regulatory scrutiny behind it. It also suppresses testosterone rather than raising it, which is the opposite of what performance-oriented use would seek. It is prohibited in male athletes under the WADA code specifically because manipulating the GnRH axis can be used to alter endogenous testosterone.